智通财经APP获悉，继昨日大跌近16%后，丽珠医药(01513)续跌超3%，盘中触及20.18港元创逾两年新低。截至发稿，跌3.33%，报20.3港元，成交额7204.9万港元。
消息面上，丽珠医药近日发布2026年中期业绩，上半年实现营业收入约50亿元人民币，同比减少20.28%；归属于母公司股东的净利润9.32亿元，同比减少27.23%。单看二季度，公司实现营业收入为21.3亿元，同比下降31.1%；归母净利润为3.55亿元，同比下降44.9%。
具体业务来看，化学制剂与中药制剂业绩的大幅下滑，成为拖累公司整体营收的主要因素。报告期内，化学制剂业务板块的销售收入下降了25.33%，主要受医保降价和国家集采的影响；中药制剂及其他业务板块的销售收入则下降34.83%。归因于今年一季度国内流感及呼吸道疾病发病率回落，导致相关产品的需求下降。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.